Breaking News

Monday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
GMDA Gamida Cell $5.10 0.01 (0.20%) 14:49 12/09/19 12/09 14:49 12/09/19 14:49 Hot Stocks	Gamida Cell announces results from Phase 1 clinical study of GDA-201 » Gamida Cell announced… Gamida Cell announced updated results from a Phase 1 clinical study of GDA-201, an investigational, natural killer cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma, or NHL, and multiple myeloma, or MM, at the 61st Annual Meeting of the American Society of Hematology, ASH, which is being held December 7-10 in Orlando, Florida. Data from 22 patients in the ongoing study showed GDA-201 in combination with monoclonal antibodies was generally well tolerated and demonstrated early evidence of clinical activity in heavily pre-treated patients, including five complete responses observed among nine patients with NHL. Gamida Cell plans to initiate a Phase 1/2 multi-dose, multi-center study of GDA-201 in patients with NHL in 2020. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a week ago
GMDA Gamida Cell $4.85 -0.02 (-0.41%) 17:16 11/14/19 11/14 17:16 11/14/19 17:16 Syndicate	Breaking Syndicate news story on Gamida Cell » Gamida Cell files to sell… Gamida Cell files to sell 3.04M ordinary shares for holders 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec
GMDA Gamida Cell $4.85 -0.02 (-0.41%) 17:16 11/14/19 11/14 17:16 11/14/19 17:16 Syndicate	Breaking Syndicate news story on Gamida Cell » Gamida Cell files $150M… Gamida Cell files $150M mixed securities shelf 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec

Over a month ago
GMDA Gamida Cell $4.87 -0.11 (-2.21%) 16:02 11/13/19 11/13 16:02 11/13/19 16:02 Earnings	Gamida Cell reports Q EPS (30c), consensus (36c) » As of September 30, 2019,… As of September 30, 2019, Gamida Cell had total cash, cash equivalents and available-for-sale assets of $68.1M, compared to $60.7Mas of December 31, 2018. Gamida Cell continues to expect cash used for ongoing operating activities in 2019 to range from $35M to $40M, reflecting anticipated expenditures to advance the company's clinical programs. Gamida Cell expects that its current cash, cash equivalents and available-for-sale securities will support the company's ongoing operating activities into the fourth quarter of 2020. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Nov 07 Dec
GMDA Gamida Cell $5.05 0.05 (1.00%) 04:55 11/08/19 11/08 04:55 11/08/19 04:55 Conference/Events	Gamida Cell management to meet with JMP Securities » Meeting to be held in New… Meeting to be held in New York on November 8 hosted by JMP Securities. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Nov 13 Nov 07 Dec

GMDA Gamida Cell $5.03 (0.00%) 09:43 11/05/19 11/05 09:43 11/05/19 09:43 Conference/Events	Gamida Cell management to meet with JMP Securities » Meeting to be held in New… Meeting to be held in New York on November 8 hosted by JMP Securities. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	08 Nov 13 Nov 07 Dec
GMDA Gamida Cell $4.38 0.21 (5.04%) 06:48 09/20/19 09/20 06:48 09/20/19 06:48 Initiation	Gamida Cell initiated at JMP Securities » Gamida Cell initiated… Gamida Cell initiated with an Outperform at JMP Securities. JMP Securities analyst Jason Butler initiated Gamida Cell with an Outperform rating and a price target of $16. The analyst cites expected phase 3 results from the company's lead program of omidubicel in stem cell transplants some time in the first half of 2020, which he calls the primary value driver for the stock. Butler assigns a 75% chance of approval for omidubicel with modeled sales of about $580M by 2027. The analyst further points to Gamida Cell's second clinical program, GDA-201, which "leverages natural killer cells" to provide an immunotherapy for cancer. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a quarter ago
GMDA Gamida Cell $3.90 -0.11 (-2.74%) 08:05 09/11/19 09/11 08:05 09/11/19 08:05 Hot Stocks	Gamida Cell, CIBMTR announce research agreement for HSTC patient data » Gamida Cell and the… Gamida Cell and the Center for International Blood and Marrow Transplant Research, or CIBMTR, announced the entry into a research agreement to collect and analyze health outcomes data in patients with hematologic malignancies who receive an allogeneic hematopoietic stem cell transplant, or HSCT, from various donor sources. The CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy worldwide. The newly launched observational study by the CIBMTR and Gamida Cell will include both retrospective and prospective data contemporaneous to the international, randomized, Phase 3 study of omidubicel, Gamida Cell's investigational advanced cell therapy designed to enhance the life-saving benefits of bone marrow transplant. Topline data from the ongoing Phase 3 study is anticipated in the first half of 2020, and initial data from the multi-year observational study is anticipated next year. Omidubicel has not yet been approved for marketing in the United States or any other jurisdiction. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GMDA Gamida Cell $3.51 0.305 (9.53%) 04:55 08/22/19 08/22 04:55 08/22/19 04:55 Conference/Events	Gamida Cell management to meet with RBC Capital » Meeting to be held in… Meeting to be held in Dallas on August 22 hosted by RBC Capital. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Aug
GMDA Gamida Cell $3.25 -0.1 (-2.99%) 14:08 08/14/19 08/14 14:08 08/14/19 14:08 Conference/Events	Gamida Cell management to meet with RBC Capital » Meeting to be held in… Meeting to be held in Dallas on August 22 hosted by RBC Capital. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	22 Aug

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial